The triple-transgenic Alzheimer (3 x Tg-AD) mouse expresses mutant PS1(M146V), APP(swe), and tau(P301L) transgenes and progressively develops plaques and neurofibrillary tangles with a temporal-and region-specific profile that resembles the neuropathological progression of Alzheimer's disease (AD). In this study, we used proteomic approaches such as two-dimensional gel electrophoresis and mass spectrometry to investigate the alterations in protein expression occurring in the brain and cerebellum of 3 x Tg-AD and presenilin-1 (PS1) knock-in mice (animals that do not develop A beta- or tau-dependent pathology nor cognitive decline and were used as control). Finally, using the Ingenuity Pathway Analysis we evaluated novel networks and molecula...
Glucose hypometabolism is the earliest symptom observed in the brains of Alzheimer disease (AD) pati...
BackgroundGenetic mutations underlying familial Alzheimer's disease (AD) were identified decades ago...
We have reported transgenic mice with neuronal overexpression of the clinical mutant beta -amyloid p...
Alzheimer's disease (AD) is characterized by amyloid-beta (Aβ)-containing plaques, neurofibrillary t...
Background Alzheimers disease (AD), the most common neurodegenerative disorder, is ...
Abstract Background Alzheimer’s disease (AD), the most common neurodegenerative disorder, is charact...
Alzheimer's disease is characterized by the presence of 2 neuropathological lesions: neurofibrillary...
Alzheimer's disease (AD) constitutes the most prevalent form of dementia. There is no cure so there ...
One of the landmarks of Alzheimer's disease are neurofibrillary tangles (NFT) in the brain. NFT main...
Glucose hypometabolism is the earliest symptom observed in the brains of Alzheimer disease (AD) pati...
Amyloid beta (Aβ) peptides impair multiple cellular pathways and play a causative role in Alzheimer’...
UnrestrictedNeuritic plaques comprised of amyloid ß (Aß) are one of the primary neuropathological ha...
ABSTR ACT: Transgenic (Tg) mouse models of Alzheimer’s disease (AD) have been extensively used to st...
Alzheimer\u27s disease (AD) is characterized by anterograde amnesia followed by a progressive declin...
Tauopathies encompass several of the most prevalent neurodegenerative diseases that consistently pro...
Glucose hypometabolism is the earliest symptom observed in the brains of Alzheimer disease (AD) pati...
BackgroundGenetic mutations underlying familial Alzheimer's disease (AD) were identified decades ago...
We have reported transgenic mice with neuronal overexpression of the clinical mutant beta -amyloid p...
Alzheimer's disease (AD) is characterized by amyloid-beta (Aβ)-containing plaques, neurofibrillary t...
Background Alzheimers disease (AD), the most common neurodegenerative disorder, is ...
Abstract Background Alzheimer’s disease (AD), the most common neurodegenerative disorder, is charact...
Alzheimer's disease is characterized by the presence of 2 neuropathological lesions: neurofibrillary...
Alzheimer's disease (AD) constitutes the most prevalent form of dementia. There is no cure so there ...
One of the landmarks of Alzheimer's disease are neurofibrillary tangles (NFT) in the brain. NFT main...
Glucose hypometabolism is the earliest symptom observed in the brains of Alzheimer disease (AD) pati...
Amyloid beta (Aβ) peptides impair multiple cellular pathways and play a causative role in Alzheimer’...
UnrestrictedNeuritic plaques comprised of amyloid ß (Aß) are one of the primary neuropathological ha...
ABSTR ACT: Transgenic (Tg) mouse models of Alzheimer’s disease (AD) have been extensively used to st...
Alzheimer\u27s disease (AD) is characterized by anterograde amnesia followed by a progressive declin...
Tauopathies encompass several of the most prevalent neurodegenerative diseases that consistently pro...
Glucose hypometabolism is the earliest symptom observed in the brains of Alzheimer disease (AD) pati...
BackgroundGenetic mutations underlying familial Alzheimer's disease (AD) were identified decades ago...
We have reported transgenic mice with neuronal overexpression of the clinical mutant beta -amyloid p...